# MEDICAL DEVICE DEVELOPMENT FROM LAB BENCH TO BEDSIDE

12 April 2016, 18:00 One Birdcage Walk, London

### FREE AND OPEN TO ALL



#### PRESENTED BY:

Daniel Green

CEO, Yaqrit Ltd and Principal Fellow in Entrepreneurship, Department of Bioengineering, Imperial College London

# MEDICAL DEVICE DEVELOPMENT FROM LAB BENCH TO BEDSIDE

12 APRIL 2016

6677

UNDERSTAND THE REQUIREMENTS OF GETTING A MEDICAL DEVICE FROM CONCEPT TO PRODUCTION WITH END-TO-END EXPERIENCES OF MEDICAL COMPANIES LARGE AND SMALL.

The UK has a strong medical device innovation record, both from academia and private research. A regular stream of devices emerge from biomedical engineering laboratories but fail to make it in the mainstream market as a result of the complex, highly regulated development market.

Devices are dependent on intellectual property protection and complicated by the need to demonstrate both clinical efficacy and economic benefit, which requires extensive clinical trials and validation before sales are achievable.

Attend this lecture and hear practical experiences of how to manage the translational research journey for new medical devices, from initial laboratory concept to marketed medical device.

#### YOU MAY BE INTERESTED IN:



### ESSENTIAL MANAGEMENT SKILLS FOR ENGINEERS

20–22 April 2016
Warwick University, Coventry
www.imeche.org/events/TLE6351



DANIEL GREEN
CEO, Yagrit Ltd and Principal Fellow
in Entrepreneurship, Department of
Bioengineering, Imperial College London

Daniel Green has been a serial CEO, venture capitalist and Financial Times correspondent all in the field of life sciences. Currently he is CEO of Yaqrit Limited, a UCL spinout company that produce devices to treat liver disease. He is also Principal Fellow in Entrepreneurship in the Department of Bioengineering at Imperial College London. In 1998, he joined the first of three venture capital firms, during which time he served on the board of companies in the US, UK and France. Yaqrit began operations in 2014 and has since attracted 66 million in grant funding from the EU's H2020 programme, as well as £2 million in Series A investor financing, with clinical trials scheduled to start this year.



FOR MORE INFORMATION:

VISIT: www.imeche.org/events/

TLE6351

CALL: +44 (0)20 7973 1258

EMAIL: eventenquiries@imeche.org



**18.00** Registration and light refreshments

**18.30** Lecture begins

20.00 Q&A session and lecture concludes

20.30 Networking drinks reception